US pharmaceutical group Pfizer has insisted it will get maximum value for its shareholders out of any move to separate its infant nutrition business. 

“The nutrition business is a highly-valued asset, and our decision about strategic options will be driven by value creation for the business and delivering the best after-tax value for our shareholders,” a spokesperson for the company told just-food today (18 April).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Reports have suggested that Pfizer is nearing a deal to sell its infant nutrition unit for US$9-10bn. 

An announcement on the move is expected as early as next week, with European food majors Nestle and Danone cited as potential buyers. 

Pfizer declined to comment directly on the reports. However, the spokesperson added “no decisions have been made” and insisted the group is in the “ongoing” process of “exploring strategic alternatives” for the unit.

When contacted by just-food Nestle declined to comment, while Danone was not immediately available for comment.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.